

# Allosteric Modulation of $\beta_2$ -Adrenergic Receptor by $Zn^{2+}$

GAYATHRI SWAMINATH, JACQUELINE STEENHUIS, BRIAN KOBILKA, and TAE WEON LEE

Howard Hughes Medical Institute, Stanford University Medical School, Stanford, California

Received April 12, 2001; accepted September 26, 2001

This paper is available online at <http://molpharm.aspetjournals.org>

## ABSTRACT

$Zn^{2+}$  is abundant in the brain, where it plays a role in the function of a number of enzymes, structural proteins, and transcription factors.  $Zn^{2+}$  is also found in synaptic vesicles and is released into synapses achieving concentrations in the range of 100 to 300  $\mu$ M [*Proc Natl Acad Sci USA* 1997;**94**:13386-13387; *Mol Pharmacol* 1997;**51**:1015-1023]. Therefore,  $Zn^{2+}$  may play a physiological role in regulating the function of postsynaptic

channels and receptors. We characterized the effect of  $Zn^{2+}$  on the functional properties of the  $\beta_2$ -adrenergic receptor ( $\beta_2$ AR). We found that physiological concentrations of  $Zn^{2+}$  increased agonist affinity and enhanced cAMP accumulation stimulated by submaximal concentrations of the  $\beta$ AR agonist isoproterenol. These results provide evidence that  $Zn^{2+}$  released at nerve terminals may modulate signals generated by the  $\beta_2$ AR in vivo.

Several groups have used  $Zn^{2+}$  together with engineered metal ion binding sites as a method to study G protein-coupled receptor (GPCR) structure (Sheikh et al., 1996, 1999; Thirstrup et al., 1996; Elling et al., 1999). In these studies,  $Zn^{2+}$  is used as a ligand for a binding pocket introduced into a receptor by one or more histidine substitutions. This method has provided insight into the proximity and relative orientation of transmembrane domains (Thirstrup et al., 1996), as well as the mechanism of receptor activation (Sheikh et al., 1996, 1999; Elling et al., 1999). However, there is considerable evidence that  $Zn^{2+}$  may be a physiological regulator of receptor function.  $Zn^{2+}$  is an abundant ion in the central nervous system (Schetz et al., 1999) and may be present at high enough concentrations in specific synapses to have a physiological role in regulating GPCR function in vivo. The  $\beta_2$ -adrenergic receptor ( $\beta_2$ AR) mediates adrenergic responses in both the central nervous system and the sympathetic nervous system. We therefore examined the effects of  $Zn^{2+}$  on  $\beta_2$ AR function. At low concentrations (1-20  $\mu$ M),  $Zn^{2+}$  increases agonist affinity and enhances cAMP accumulation in response to submaximal concentrations of a  $\beta$ -agonist. At high concentrations (>500  $\mu$ M),  $Zn^{2+}$  alters both  $K_D$  and  $B_{max}$  values for the antagonist dihydroalprenolol (DHA). These results demonstrate that  $Zn^{2+}$  is a positive allosteric modulator of agonist binding for the  $\beta_2$ AR and suggest that  $Zn^{2+}$  may be a physiologically relevant regulator of  $\beta_2$ AR function in vivo.

This work was supported in part by National Institutes of Health grant 5-R01-NS28471 and the Mathers Charitable Foundation.

## Experimental Procedures

**Materials.** [ $^3$ H]DHA (111.8 Ci/mmol) and guanosine-5'-O-(3-[ $^{35}$ S]thio)triphosphate (GTP $\gamma$ S; 1250 Ci/mmol) were purchased from PerkinElmer Life Sciences (Boston, MA). Unlabeled GTP $\gamma$ S was purchased from Roche Molecular Biochemicals (Indianapolis, IN). GDP, zinc chloride, isoproterenol (ISO), and alprenolol were purchased from Sigma (St. Louis, MO). Nickel sulfate was obtained from Aldrich Chemical (Milwaukee, WI). Cobalt chloride was from Mallinckrodt (Chesterfield, MO). EDTA (disodium salt) was purchased from Fisher Scientific (Fair Lawn, NJ). Baculovirus expression vector pVL1392 and BaculoGold transfection kit were obtained from BD Pharmingen (San Diego, CA). SF 900 II medium was obtained from Invitrogen (Carlsbad, CA). Fetal calf serum was obtained from Gemini (Calabasas, CA) and gentamicin was obtained from Roche Molecular Biochemicals (Mannheim, Germany). Glass fiber filters (GF/C filters) and nitrocellulose filters were purchased from Schleicher & Schuell (Keene, NH).

**Membrane Preparation.** For infection, Sf9 cells were sedimented for 2 h at 1g and suspended in fresh medium. Cells were seeded at  $3.0 \times 10^6$  cells/ml, infected with recombinant baculovirus for the  $\beta_2$ AR and/or membrane-tethered  $G_{sa}$  (tet $G_{sa}$ ), and cultured for 48 h. All the membrane preparation steps were done at 4°C, as described elsewhere (Lee et al., 1999). Cells were harvested by centrifugation (10 min at 10,000g), washed once with phosphate-buffered saline and recentrifuged, and then resuspended in lysis buffer (10 mM Tris-HCl, pH 7.4, with 1 mM EDTA) and lysed using 25 strokes of a Dounce homogenizer. Nuclei and unbroken cells were removed by centrifugation (5 min at 500g). The supernatant was removed and centrifuged (30 min at 40,000g). The resulting pellet was resuspended in 20 ml of lysis buffer (10 mM Tris-HCl, pH 7.4, alone) and recentrifuged. Membranes were resuspended at 0.5 to 1.5 mg of protein/ml in binding buffer (75 mM Tris-HCl, pH 7.4) and stored at -80°C until use.

**ABBREVIATIONS:**  $\beta_2$ AR,  $\beta_2$ -adrenergic receptor; DHA, [ $^3$ H]dihydroalprenolol; GTP $\gamma$ S, guanosine-5'-O-(3-thio)triphosphate; ISO, (-)-isoproterenol; GPCR, G protein-coupled receptor; NDM, *n*-dodecyl maltoside; HEK, human embryonic kidney; PD 81,723, (2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl)phenyl]methanone.

**Urea Treatment of Membranes.** Membranes were extracted with 7 M urea to remove G protein subunits (Lim and Neubig, 2001). The urea solution was prepared by dissolution of urea crystals in a buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM  $MgCl_2$ , 1 mM EDTA with protease inhibitors (25  $\mu$ g/ml leupeptin and 16  $\mu$ g/ml benzamidine) at room temperature and then kept on ice until use. Sf9 membranes expressing the  $\beta_2AR$  were pelleted (40,000g for 10 min) and resuspended to  $\sim 1$  mg/ml in freshly prepared 7 M urea solution. The membranes were homogenized 10 times and incubated for 30 min with stirring. The membranes were centrifuged at 40,000g for 30 min then washed with 75 mM Tris-HCl, pH 7.4, containing protease inhibitors. The final pellet was resuspended to a final concentration of  $\sim 1$  mg/ml and stored in aliquots at  $-80^\circ C$ .

**Expression and Purification of  $\beta_2AR$  Receptor.** The human  $\beta_2AR$ , epitope tagged at the amino terminus with the FLAG epitope (Sigma) and tagged at the carboxy terminus with six histidines, was expressed in Sf9 cells and purified as described previously (Kobilka, 1995).

**Membrane Binding Assays.** Antagonist binding assays were done with membranes expressing  $\beta_2AR$ . Membranes (25  $\mu$ g of protein) were suspended in 500  $\mu$ l of binding buffer incubated with different concentrations of divalent ions in the presence of 1 nM [ $^3H$ ]DHA. Saturation binding experiments were done on the  $\beta_2AR$  expressed in Sf9 membranes. Membranes (50  $\mu$ g of protein) were suspended in 500  $\mu$ l of binding buffer supplemented with 100 pM to 10 nM [ $^3H$ ]dihydroalprenolol and 0.2% bovine serum albumin. The binding buffer contained only 75 mM Tris-HCl, pH 7.5. Nonspecific binding was assessed with 10  $\mu$ M alprenolol. Incubations were performed for 1 h at room temperature with shaking at 230 rpm. Competition binding experiments were carried out with 1 nM [ $^3H$ ]dihydroalprenolol in the presence of increasing concentrations of (-)-isoproterenol and different concentrations of divalent ions.

**Solubilized Binding Assays.** Binding assays on purified, detergent-solubilized receptor were carried out in 100- $\mu$ l volumes in high-salt buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, and 0.1% *n*-dodecyl maltoside). The binding assays were stopped and free [ $^3H$ ]DHA separated from bound by desalting on 2-ml Sephadex G50 column (4  $\times$  0.5 cm) by using ice-cold high-salt buffer. Nonspecific binding was determined in the presence of 10  $\mu$ M alprenolol.

**Dissociation Rate Kinetic Assay.** The effect of zinc on the rate of antagonist dissociation from  $\beta_2AR$  was examined by measuring the  $k_{off}$  in the absence and presence of 1 mM  $Zn^{2+}$ . Membranes were suspended in 75 mM Tris-HCl, pH 7.5, with 1 nM [ $^3H$ ]DHA for 30 min at room temperature (shaking at 230 rpm). At time zero, total binding was determined and a saturating amount of cold alprenolol (final  $10^{-5}$  M) or cold alprenolol (final  $10^{-5}$  M) and  $ZnCl_2$  (final concentration, 1 mM) was added to tubes containing membranes and [ $^3H$ ]DHA. Bound [ $^3H$ ]DHA was measured at 5-min intervals.

**[ $^{35}S$ ]GTP $\gamma$ S Binding.**  $\beta_2AR$  with tet $G_{sa}$  were coexpressed in Sf9 cells and membranes were prepared as described above. Membranes were pelleted by a 15-min centrifugation at  $4^\circ C$  at 15,000g and resuspended in buffer containing 75 mM Tris-HCl, pH 7.5. Sf9 membranes (10  $\mu$ g of protein/tube) were suspended in 500  $\mu$ l of magnesium binding buffer (75 mM Tris-HCl, pH 7.5, and 1 mM  $MgCl_2$ ) supplemented with 0.05% (w/v) bovine serum albumin, 1 nM [ $^{35}S$ ]GTP $\gamma$ S (0.25  $\mu$ Ci/tube), 1  $\mu$ M GDP with or without 10  $\mu$ M isoproterenol in presence or absence of  $Zn^{2+}$ . Incubations were performed at  $25^\circ C$  and shaking at 250 rpm for 1 h. Nonspecific binding was determined in the presence of 10  $\mu$ M GTP $\gamma$ S and was less than 0.2% of total binding. Bound [ $^{35}S$ ]GTP $\gamma$ S was separated from free [ $^{35}S$ ]GTP $\gamma$ S by filtration through GF/C filters, followed by three washes with 3 ml of cold magnesium binding buffer. Filter-bound radioactivity was determined by liquid scintillation counting.

**cAMP Accumulation.** The production of cAMP was determined by adenylyl cyclase activation FlashPlate assay (PerkinElmer Life Sciences), in which 96-well plates are coated with solid scintillant to which anti-cAMP antibody has been bound. Briefly, HEK293 cells expressing human  $\beta_2AR$  were detached and washed four times in  $1\times$  phosphate-buffered saline without  $Ca^{2+}/Mg^{2+}$ , and then resuspended to a density of approximately  $2 \times 10^6$  cells/ml in stimulation buffer ( $1\times$  phosphate-buffered saline, without calcium/magnesium, with 700  $\mu$ M 3-isobutyl-1-methylxanthine, 0.1% protease-free bovine serum albumin, and 0.09% chloroacetamide) from PerkinElmer Life Sciences. Ligands (25  $\mu$ l each) were diluted in Milli-Q water with various concentrations and dispensed to the flashplate. Resuspended whole cells (50  $\mu$ l) were added to the ligand-loaded plate and stimulated at  $37^\circ C$  for 10 min before lysing cells with 100  $\mu$ l of Detection Buffer (Invitrogen) containing  $^{125}I$ -cAMP, permeabilizer, and 0.09% sodium azide as provided by the manufacturer. After 2 h of incubation at room temperature, radioactivity was counted. To determine the concentrations of cAMP in the sample, cAMP standards were run in the same plate and expressed as picomoles per well.

**Miscellaneous.** Protein was determined using the DC protein assay kit (Bio-Rad, Hercules, CA). Data were analyzed by nonlinear regression analysis with Prism program (GraphPad Software, San Diego, CA).


## Results

**Effect of  $Zn^{2+}$  on Antagonist Binding.** To examine the effect of  $Zn^{2+}$  on antagonist binding, we performed radioligand binding studies by using [ $^3H$ ]DHA, a neutral antagonist. As shown in Fig. 1A, a significant effect of  $Zn^{2+}$  on DHA binding was observed only at concentrations of  $Zn^{2+} > 500 \mu$ M, where DHA binding was reduced by  $40 \pm 2\%$  (Fig. 1A). Saturation binding studies in the presence or absence of 1 mM  $Zn^{2+}$  caused an increase of nearly 3-fold in apparent  $K_D$  value for DHA ( $1.4 \pm 0.2$  nM control,  $4.9 \pm 1.2$  nM with  $Zn^{2+}$ ) with a 40% decrease in  $B_{max}$  (Fig. 1B). These results suggest that  $Zn^{2+}$  may function as a noncompetitive blocker of antagonist binding; however, we found that 1 mM  $Zn^{2+}$  slowed the rate of DHA dissociation (Fig. 1C). Moreover, the effect of  $Zn^{2+}$  on antagonist binding is not fully reversible in membrane-bound  $\beta_2AR$  (Fig. 2A). Note that  $Zn^{2+}$  also inhibits binding of antagonist to purified, detergent-solubilized  $\beta_2AR$ ; however, this inhibition is almost completely reversible after chelation of  $Zn^{2+}$  by EDTA (Fig. 2B). These results suggest that some of the effects of  $Zn^{2+}$  on antagonist binding may be caused by nonspecific effects of  $Zn^{2+}$  on phospholipids.

**Effect of  $Zn^{2+}$  on High- and Low-Affinity Agonist Binding.** We examined the effect of  $Zn^{2+}$  on agonist binding in membranes expressing the  $\beta_2AR$  with and without  $G_{sa}$ . For these experiments, we used tet $G_{sa}$ . We have shown previously that tet $G_{sa}$  couples more efficiently to  $\beta_2AR$  than does wild-type  $G_{sa}$  (Lee et al., 1999). In membranes expressing the  $\beta_2AR$  with tet $G_{sa}$ , we observed a biphasic curve with a high-affinity, GTP $\gamma$ S-sensitive component (Fig. 3). To study the effect of  $Zn^{2+}$  on agonist binding affinity, isoproterenol competition binding studies were done using 1 nM antagonist [ $^3H$ ]DHA in the presence of varying concentrations of  $Zn^{2+}$  (Fig. 4, A–C). As shown in Fig. 4A, as little as 20  $\mu$ M  $Zn^{2+}$  resulted in a change of the apparent biphasic nature of the competition curve with an increase in  $K_H$ . We also observed a decrease in  $K_L$ ,

which was even greater at  $100 \mu\text{M } Zn^{2+}$  (Fig. 4B), a concentration at which we observed no effects on antagonist binding. A smaller decrease in  $K_L$  was observed at  $1 \text{ mM } Zn^{2+}$  (Fig. 4C), a concentration that also reduces antagonist affinity. We observed similar effects on agonist binding affinity in membranes expressing the  $\beta_2$ AR without tet $G_{s\alpha}$ , where only a small amount of high-affinity binding is detected (Fig. 5A), as well as in membranes treated with  $7 \text{ M}$  urea to remove heterotrimeric G proteins (Fig. 5B). Thus, at relatively low concentrations,  $Zn^{2+}$  induces an increase in agonist affinity for the uncoupled receptor.


The receptor used in the studies described thus far contains a hexahistidine tail on the carboxyl terminus to facilitate



**Fig. 1.** Effect of zinc on antagonist binding in membranes expressing  $\beta_2$ AR. A, inhibition of  $[^3\text{H}]\text{DHA}$  binding to  $\beta_2$ AR by zinc. Sf9 membranes expressing  $\beta_2$ AR ( $15.2 \text{ pmol/mg}$ ) were incubated with different concentrations of zinc in the presence of  $1 \text{ nM } [^3\text{H}]\text{DHA}$ . The DHA binding in the absence of zinc is referred to as basal binding and was set to 100%. Maximum inhibition of antagonist binding was around  $1 \text{ mM } Zn^{2+}$ . B, saturation binding of  $[^3\text{H}]\text{DHA}$  ( $100 \text{ pM}$ – $20 \text{ nM}$ ) on membranes expressing  $\beta_2$ AR ( $8.7 \text{ pmol/mg}$ ) in the presence and absence of  $1 \text{ mM } Zn^{2+}$ .  $Zn^{2+}$  caused an increase of nearly 3-fold in apparent  $K_D$  value for DHA ( $1.489 \pm 0.23 \text{ nM}$  control,  $4.877 \pm 1.178 \text{ nM}$  with  $Zn^{2+}$ ) and  $\sim 40\%$  decrease in  $B_{\text{max}}$  value. Data were best fit to monophasic saturation hyperbolae. These data are representative of three different experiments done in triplicate. C, effect of zinc on the rate of antagonist dissociation from  $\beta_2$ AR. Dissociation rate kinetics measured for  $[^3\text{H}]\text{DHA}$  binding to membranes expressing  $\beta_2$ AR ( $7 \text{ pmol/mg}$ ) was determined in the presence (triangles) or absence (squares) of  $1 \text{ mM } Zn^{2+}$  as described under *Experimental Procedures*. Data shown are the mean  $\pm$  S.D. of three independent experiments performed in triplicate.

tate receptor purification. However, we observed identical effects of  $Zn^{2+}$  on antagonist binding (data not shown) and on agonist binding in membranes expressing a  $\beta_2$ AR without a carboxyl-terminal hexahistidine sequence (Fig. 5C). Therefore, binding of  $Zn^{2+}$  to this carboxyl-terminal hexahistidine sequence is not responsible for the observed effects of  $Zn^{2+}$  on receptor function.

To further investigate the effect of  $Zn^{2+}$  on the GTP $\gamma$ S-insensitive agonist binding affinity, we performed a modified competition binding experiment in which  $100 \text{ nM}$  isoproterenol competes for binding sites with  $1 \text{ nM } [^3\text{H}]\text{DHA}$  in the presence of  $10 \mu\text{M}$  GTP $\gamma$ S and varying concentrations of  $Zn^{2+}$  (Fig. 6A). Also shown is the effect of  $Zn^{2+}$  on  $[^3\text{H}]\text{DHA}$  binding in the absence of isoproterenol. In the presence of increasing concentrations of  $Zn^{2+}$ ,  $100 \text{ nM}$  isoproterenol becomes more effective at displacing  $[^3\text{H}]\text{DHA}$ . The maximal effect of  $Zn^{2+}$  on isoproterenol affinity occurs at  $\sim 30 \mu\text{M}$  with an  $\text{IC}_{50}$  of  $3.0 \mu\text{M}$ . Similar results were obtained with membranes that had been extracted with  $7 \text{ M}$  urea to remove G proteins (Fig. 6B).




**Fig. 2.** Reversibility of the  $Zn^{2+}$  effect on antagonist binding. Membrane-bound (A) or purified  $\beta_2$ AR (B) was preincubated with either  $1 \text{ mM } ZnCl_2$ ,  $5 \text{ mM}$  EDTA, or nothing for  $30 \text{ min}$  on ice. After the pretreatment period, radioligand ( $2 \text{ nM } [^3\text{H}]\text{DHA}$ ) and either  $5 \text{ mM}$  EDTA or nothing was added and incubated for  $1 \text{ h}$  at room temperature. The membranes were then harvested by rapid filtration and soluble receptor was harvested by gel filtration as described under *Experimental Procedures*. Data shown are the mean  $\pm$  S.D. of three independent experiments performed either in duplicate for purified protein or triplicate for membranes.

To confirm that the  $Zn^{2+}$ -mediated increase in agonist affinity was caused by a direct interaction between  $Zn^{2+}$  and the  $\beta_2AR$ , we examined the influence of  $Zn^{2+}$  on purified, detergent-solubilized  $\beta_2AR$ . As shown in Fig. 6C,  $Zn^{2+}$  enhanced the ability of 1  $\mu M$  isoproterenol to displace [ $^3H$ ]DHA in a soluble binding assay.

**Effects of  $Ni^{2+}$  and  $Co^{2+}$  on Agonist and Antagonist Binding.** To determine the specificity of the functional effects of  $Zn^{2+}$  on receptor function we compared the effect of  $Ni^{2+}$  and  $Co^{2+}$  on agonist and antagonist binding (Fig. 7).  $Co^{2+}$  had an effect on agonist affinity similar to  $Zn^{2+}$ , but no significant effect on antagonist affinity (Fig. 7A).  $Ni^{2+}$  had no significant effect on either agonist or antagonist affinity (Fig. 7B).


**Inhibition of Gs Function by  $Zn^{2+}$ .** Our competition binding studies (Fig. 4) suggest that  $Zn^{2+}$  uncouples the receptor from Gs. To further examine the effect of  $Zn^{2+}$  on the interaction of the  $\beta_2AR$  and  $G_{s\alpha}$ , receptor-mediated GTP $\gamma$ S binding was performed in Sf9 membranes coexpressing  $\beta_2AR$  and tet $G_{s\alpha}$ . Consistent with the results of Sheikh et al. (1999), we found that  $Zn^{2+}$  inhibited stimulation of GTP $\gamma$ S binding by the agonist isoproterenol with an  $IC_{50}$  of 7.2  $\mu M$  (Fig. 8). However, we also found that  $Zn^{2+}$  inhibited basal GTP $\gamma$ S binding to purified  $G_{s\alpha}$  (data not shown), suggesting that the uncoupling of  $\beta_2AR$  and Gs is caused by a direct effect of  $Zn^{2+}$  on  $G_{s\alpha}$ , possibly by competing for the  $Mg^{2+}$  binding site.

**Effect of  $Zn^{2+}$  on Isoproterenol-Stimulated cAMP Accumulation.** The studies described above were done on membrane fragments or purified receptor in which  $Zn^{2+}$  has equal access to both cytoplasmic and extracellular domains of the  $\beta_2AR$ . Therefore, they do not provide information about the location of the  $Zn^{2+}$  binding site(s) responsible for the functional effects of  $Zn^{2+}$  on agonist and antagonist binding. In vivo,  $Zn^{2+}$  released from synaptic vesicles would have access to extracellular domains of the receptor. Diffusion or transport of  $Zn^{2+}$  across the plasma membrane would limit access to intracellular domains. We therefore examined the effect of  $Zn^{2+}$  on isoproterenol-stimulated cAMP accumulation in intact HEK293 cells expressing the wild-type (non-histidine-tagged)  $\beta_2AR$ . Iso-



**Fig. 3.** Effect of GTP $\gamma$ S on isoproterenol competition of DHA binding to Sf9 membranes expressing  $\beta_2AR$  together with tet $G_{s\alpha}$ . Isoproterenol competition in presence and absence of unlabeled GTP $\gamma$ S (10  $\mu M$ ) was performed as described under *Experimental Procedures*. Reaction mixtures contained 10  $\mu g$  of protein/tube. The membranes expressing the protein were 15.7 pmol/mg. Data shown are the mean  $\pm$  S.D. of three independent experiments performed in triplicate. Binding data were analyzed for best fit to two affinity states.

proterenol dose-response studies revealed that at  $Zn^{2+}$  concentrations 100  $\mu M$  or greater the maximal cAMP accumulation was decreased (Fig. 9A). When these data were plotted as the percentage of the maximal isoproterenol-stimulated cAMP, we observed a small decrease in  $EC_{50}$  in the presence of 1  $\mu M$   $Zn^{2+}$  (Fig. 9B). To further examine the effect of  $Zn^{2+}$  on isoproterenol-stimulated cAMP accumulation, cells were exposed to increasing concentrations of  $Zn^{2+}$  in the presence of 0 to 1 nM isoproterenol. Maximal cAMP accumulation was observed at 1  $\mu M$   $Zn^{2+}$  in the presence of isoproterenol, but  $Zn^{2+}$  had no effect in the absence of isoproterenol (Fig. 9C). Moreover,  $Zn^{2+}$  did not



**Fig. 4.** Modulation of agonist binding by  $Zn^{2+}$ . A to C, isoproterenol competition binding was performed on membranes expressing  $\beta_2AR$  (12.7 pmol/mg) together with tet $G_{s\alpha}$  in the presence of 20  $\mu M$   $Zn^{2+}$  (A), 100  $\mu M$   $Zn^{2+}$  (B), and 1 mM  $Zn^{2+}$  (C). The antagonist binding observed in the absence of any competitor was set to 100%. In A to C, binding in the absence of  $Zn^{2+}$  is shown for reference. In the presence of 20 to 100  $\mu M$   $Zn^{2+}$ , GTP $\gamma$ S-sensitive high-affinity binding is lost, yet the affinity of the low-affinity binding is increased. Reaction mixtures contained 1 nM [ $^3H$ ]DHA and isoproterenol at the indicated concentrations. Binding data were analyzed for best fit to two affinity states. Data represent the mean of three independent experiments. Each experiment was performed in triplicate.


augment cAMP accumulation stimulated by either 10 or 100  $\mu$ M forskolin (Fig. 9D).

## Discussion


Our results demonstrate that at micromolar concentrations,  $Zn^{2+}$  is a positive allosteric modulator of agonist binding; at higher concentrations,  $Zn^{2+}$  has complex effects on antagonist binding. Allosteric modulation of ligand binding

has been observed for several GPCRs. These modulators include physiologically relevant ions as well as small organic molecules. A large number of compounds allosterically increase binding affinity for muscarinic receptor antagonists. Allosteric regulation can be demonstrated in all five subtypes of muscarinic receptors, but the m2 receptor seems to be the most sensitive (Tucek and Proska, 1995). Although most allosteric modulators for the muscarinic receptors primarily affect antagonist binding, allosteric modulation of agonist binding has also been described previously (Jakubik et al., 1997).

In addition to the muscarinic receptor, allosteric compounds have been identified for the A1 adenosine receptor. The 2-amino-3-benzoylthiophene PD 81,723 has been shown to enhance agonist binding and G protein coupling in a  $Mg^{2+}$ -dependent manner (Bhattacharya and Linden, 1995; Musser et al., 1999).



**Fig. 5.** Effect of  $Zn^{2+}$  on agonist binding does not depend on Gs. A, effect of 20  $\mu$ M  $Zn^{2+}$  on agonist binding affinity in Sf9 membranes expressing  $\beta_2$ AR without tetG<sub>sa</sub>. Isoproterenol competition binding experiments were performed as described under *Experimental Procedures*. The competition binding was performed with 1 nM [ $^3$ H]DHA in the presence of different concentrations of isoproterenol with and without 20  $\mu$ M  $Zn^{2+}$ . B, competition binding experiments performed on membranes treated with 7 M urea to remove G proteins. Urea treatment of membranes is described under *Experimental Procedures*. Experiments shown in A and B above were done on membranes expressing the  $\beta_2$ AR with a carboxyl-terminal hexahistidine sequence. C, effect of 20  $\mu$ M  $Zn^{2+}$  on agonist binding affinity in membranes expressing  $\beta_2$ AR without a carboxy-terminal His tag. Data represent the mean of two independent experiments. Each experiment was done in triplicate.




**Fig. 6.** Effect of zinc on the agonist affinity. A, effect of  $Zn^{2+}$  on [ $^3$ H]DHA binding in presence and absence of 100 nM isoproterenol was determined using Sf9 membranes expressing  $\beta_2$ AR (7 pmol/mg). Assay mixtures contained  $\sim$ 25  $\mu$ g of membrane protein, 1 nM [ $^3$ H]DHA, and 10  $\mu$ M GTP $\gamma$ S. Nonspecific binding was less than 10% of total binding. Data represent the mean  $\pm$  S.D. of three independent experiments. Each of these experiments was performed in triplicate. B, effect of  $Zn^{2+}$  on agonist affinity in urea-treated membranes expressing  $\beta_2$ AR (12.6 pmol/mg). The reaction mixtures contained  $\sim$ 20  $\mu$ g of membrane protein and 2 nM [ $^3$ H]DHA. Data represent the mean  $\pm$  S.D. of two independent experiments. Each of these experiments was performed in triplicate. C, effect of  $Zn^{2+}$  on agonist affinity in purified, detergent-solubilized  $\beta_2$ AR. Soluble binding was performed as described under *Experimental Procedures*. The assay mixture contained purified receptor, with or without 1  $\mu$ M isoproterenol, and 2 nM [ $^3$ H]DHA, in the absence or presence of the indicated concentrations of zinc. Data obtained were from three independent experiments done in duplicate. All the binding data were analyzed for best fit to two affinity states.

The function of several Gi-coupled receptors has been shown to be modulated by amiloride analogs and by  $\text{Na}^+$ . This effect has been particularly well characterized for the  $\alpha_2$ -adrenergic receptor (Motulsky and Insel, 1983; Limbird, 1984; Horstman et al., 1990) and for the dopamine D2 (Neve, 1991) and D4 subtypes (Schetz and Sibley, 2001).  $\text{Na}^+$  both uncouples the receptor from Gi and reduces agonist affinity. The  $\text{Na}^+$ -sensitive site has been identified in the  $\alpha_2$ -adrenergic receptor (Horstman et al., 1990) and the D4 dopamine receptor (Schetz and Sibley, 2001) as a conserved Asp residue within the cytoplasmic side of transmembrane 2. This  $\text{Na}^+$  sensitivity may be physiologically relevant, because relatively high local concentrations may be achieved near the cytoplasmic side of the receptor after membrane depolarization.


Recently, the function of the calcium receptor has been shown to be positively modulated by certain L-amino acids (Conigrave et al., 2000a,b). This may be physiologically relevant because nutrient and  $\text{Ca}^{2+}$  homeostasis may be regulated in a coordinate manner.

$\text{Zn}^{2+}$  is an abundant divalent cation in the central nervous system and is released from some synaptic vesicles

A



B




**Fig. 7.** Effect of divalent ions on the agonist affinity. The effect of  $\text{Co}^{2+}$  (A) and  $\text{Ni}^{2+}$  (B) on  $[^3\text{H}]\text{DHA}$  binding in presence and absence of 100 nM isoproterenol was determined using Sf9 membranes expressing  $\beta_2\text{AR}$  (7 pmol/mg). Assay mixtures contained  $\sim 25 \mu\text{g}$  of membrane protein, 1 nM  $[^3\text{H}]\text{DHA}$ , and 10  $\mu\text{M}$   $\text{GTP}\gamma\text{S}$ . Nonspecific binding was less than 10% of total binding. Data represent the mean  $\pm$  S.D. of three independent experiments. Each of these experiments was performed in triplicate. Binding data were analyzed for best fit to two affinity states.

(Schetz et al., 1999; Weiss et al., 2000).  $\text{Zn}^{2+}$  has been shown to be a noncompetitive blocker of dopamine uptake by the dopamine transporter (Norregaard et al., 1998) and modulates the function of several ligand-gated ion channels. Glycine-induced currents in freshly dissociated rat dorsal motor nucleus neurons are potentiated at low concentrations of  $\text{Zn}^{2+}$  ( $< 3 \mu\text{M}$ ) but inhibited at higher concentrations ( $> 10 \mu\text{M}$ ) (Doi et al., 1999).  $\text{Zn}^{2+}$  inhibits  $\gamma$ -aminobutyrate currents by slowing the transition rate from closed to open and by accelerating the deactivation kinetics (Barberis et al., 2000). Of particular interest is the observation that relatively low concentrations of  $\text{Zn}^{2+}$  ( $\sim 10 \mu\text{M}$ ) potentiate both agonist binding and peak current in the 5-hydroxytryptamine 3 receptor (Hubbard and Lummis, 2000).

Less is known about the regulation of G protein-coupled receptor function by  $\text{Zn}^{2+}$ . At relatively high concentrations ( $> 100 \mu\text{M}$ ),  $\text{Zn}^{2+}$  has been shown to inhibit antagonist binding to the dopamine receptor (D1, D2, and D4 subtypes) (Schetz and Sibley, 1997, 2001). However, the effect of  $\text{Zn}^{2+}$  on agonist binding or G protein activation was not examined. In the case of the D4 dopamine receptor, the  $\text{Zn}^{2+}$  binding site that alters antagonist binding is different from the  $\text{Na}^+$  binding site (Schetz and Sibley, 2001).  $\text{Zn}^{2+}$  at high concentrations ( $> 1 \text{ mM}$ ) also inhibits binding to the M1 muscarinic receptor (Lu and Hulme, 2000) and the  $\mu$ -opioid receptor (Thirstrup et al., 1996). However, to our knowledge, there has been no report of  $\text{Zn}^{2+}$  increasing agonist affinity at these or other GPCRs.

Our findings with the human  $\beta_2\text{AR}$  constitute the first report of  $\text{Zn}^{2+}$  as a positive allosteric modulator of agonist binding for a GPCR. The effect of  $\text{Zn}^{2+}$  on agonist binding is caused by a direct effect of  $\text{Zn}^{2+}$  on the  $\beta_2\text{AR}$ , because it was observed in membranes treated with 7 M urea, a concentration shown previously to strip membranes of both  $\alpha$  and  $\beta\gamma$  G protein subunits (Lim and Neubig, 2001) (Fig. 5B). Moreover, we observed that  $\text{Zn}^{2+}$  enhanced agonist affinity in purified  $\beta_2\text{AR}$  (Fig. 6B).

While enhancing agonist affinity,  $\text{Zn}^{2+}$  seems to uncouple the receptor from Gs, probably due to a direct effect of  $\text{Zn}^{2+}$  on Gs, because  $\text{Zn}^{2+}$  inhibited basal  $\text{GTP}\gamma\text{S}$  binding to puri-



**Fig. 8.** Effect of  $\text{Zn}^{2+}$  on  $[^{35}\text{S}]\text{GTP}\gamma\text{S}$  binding in Sf9 membranes coexpressing  $\beta_2\text{AR}$  (12.7 pmol/mg) and  $\text{tetG}_{\text{s}\alpha}$ .  $\text{GTP}\gamma\text{S}$  binding was done on Sf9 membranes in presence of different concentrations of zinc. (—) Iso-proterenol (10  $\mu\text{M}$ ) was used as agonist.  $\text{Zn}^{2+}$  inhibits receptor-stimulated  $\text{GTP}\gamma\text{S}$  binding to  $\text{tetG}_{\text{s}\alpha}$  ( $\text{IC}_{50}$  of 7.2  $\mu\text{M}$ ) (left). The effect of  $\text{Zn}^{2+}$  on  $\text{GTP}\gamma\text{S}$  binding to membranes expressing  $\text{tetG}_{\text{s}\alpha}$  alone (right).


fied Gs (data not shown). GTP binds to  $G_{\alpha s}$  as a GTP-Mg $^{2+}$  complex (Birnbaumer and Birnbaumer, 1995).  $Zn^{2+}$  may form a complex with GTP or interact directly with the Mg $^{2+}$  binding site on  $G_{\alpha s}$ . However, in intact cells, we observed a small increase in isoproterenol-stimulated cAMP accumulation (Fig. 9B). This stimulatory effect of  $Zn^{2+}$  on cAMP accumulation is most probably caused by a direct effect of  $Zn^{2+}$  on the  $\beta_2$ AR, rather than on downstream signaling components, for several reasons. The plasma membrane limits access of  $Zn^{2+}$  to intracellular signaling components. We observe no effect of  $Zn^{2+}$  in the absence of the  $\beta$ -agonist. As discussed above, the effect of  $Zn^{2+}$  on Gs is inhibitory and occurs at  $Zn^{2+}$  concentrations greater than 1  $\mu$ M. This inhibitory effect may explain the inhibition of cAMP accumulation that we observe at higher  $Zn^{2+}$  concentrations (Fig. 9). Moreover,  $Zn^{2+}$  has been reported to be an inhibitor of adenylyl cyclase (Tesmer et al., 1999). Finally, the cAMP accumulation experiments were done in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, and  $Zn^{2+}$  did not augment cAMP-stimulated by forskolin (Fig. 9D). Therefore, the effect of  $Zn^{2+}$  cannot be explained by inhibition of cAMP hydrolysis. Therefore, we would predict that the  $Zn^{2+}$  enhances cAMP accumulation by an interaction with an extracellular domain of the  $\beta_2$ AR, possibly the same domain responsible for the positive allosteric effect on agonist binding.

The effect of  $Zn^{2+}$  on antagonist binding seems to be biphasic (Figs. 1A and 5A). A small (<20%) decrease in antagonist binding occurs with an  $IC_{50}$  comparable with that for the  $Zn^{2+}$  effect on agonist affinity ( $\sim 5 \mu$ M; Fig. 5A); however, a larger effect is observed at concentrations >100  $\mu$ M. At 1 mM  $Zn^{2+}$ , both  $B_{max}$  and  $K_D$  values for [ $^3$ H]DHA binding are altered, consistent with the idea that  $Zn^{2+}$  is a noncompetitive blocker of this antagonist. However,  $Zn^{2+}$  also slows the rate of [ $^3$ H]DHA dissociation (Fig. 1C), and the effects of 1

mM  $Zn^{2+}$  on antagonist binding are not fully reversible in membrane-bound receptor (Fig. 2A). The fact that binding is almost completely reversible in purified, detergent-soluble receptor suggests that some of the effects of  $Zn^{2+}$  on antagonist binding may be caused by interactions between  $Zn^{2+}$  and phospholipids. Previous studies showed that  $Zn^{2+}$  can alter the properties of phospholipids by interactions with the polar head groups (Binder et al., 2001). Thus, the effects of  $Zn^{2+}$  on antagonist binding are complex and cannot be explained by noncompetitive inhibition. However, because these effects occur only at relatively high concentrations of  $Zn^{2+}$  (>100  $\mu$ M), they are not likely to be physiologically important.

Our results are consistent with the existence of at least two  $Zn^{2+}$  binding sites in the  $\beta_2$ AR, one primarily affecting agonist binding and one primarily affecting antagonist binding. This is further supported by the differential effects of other divalent cations on agonist and antagonist binding. Like  $Zn^{2+}$ ,  $Co^{2+}$  enhances agonist binding but has no significant effect on antagonist binding (Fig. 7A).  $Ni^{2+}$  has only a small effect on antagonist binding, but no significant effect on agonist binding (Fig. 7B). Thus, the divalent cation binding site influencing agonist binding can accommodate  $Zn^{2+}$  and  $Co^{2+}$ , but not  $Ni^{2+}$ , whereas the binding site influencing antagonist binding accommodates  $Zn^{2+}$  and to a much lesser extent  $Ni^{2+}$ , but not  $Co^{2+}$ .

In conclusion,  $Zn^{2+}$  has complex effects on the functional properties of the  $\beta_2$ AR.  $Zn^{2+}$  binding to a high affinity site ( $IC_{50}$  of  $\sim 5 \mu$ M) enhances agonist affinity and agonist-stimulated cAMP accumulation.  $Zn^{2+}$  binding to a low-affinity site ( $IC_{50}$  of >500  $\mu$ M) inhibits antagonist binding, yet slows antagonist dissociation. The effects of  $Zn^{2+}$  on agonist binding and cAMP accumulation occur at concentrations of  $Zn^{2+}$  that may be achieved within a synapse.



**Fig. 9.** Effect of zinc on isoproterenol-stimulated cAMP accumulation in HEK293 cells. A, ISO dose-response studies were done in HEK293 cells expressing nonhistidine-tagged  $\beta_2$ AR in the presence of 0, 1, and 1000  $\mu$ M  $Zn^{2+}$ . The cAMP assay was performed as described under *Experimental Procedures*. B, data in A replotted as the percentage of the maximal isoproterenol-stimulated cAMP to facilitate comparison of the effects of  $Zn^{2+}$  on the  $EC_{50}$  for isoproterenol. C,  $Zn^{2+}$  dose-response studies done in the presence of 0, 0.1, 0.3, 0.6, and 1 nM ISO. D,  $Zn^{2+}$  dose-response studies done in the presence of 10 and 100  $\mu$ M forskolin. Data represented are from three independent experiments performed in triplicate.

Thus,  $Zn^{2+}$  may be a physiological modulator of  $\beta_2AR$  function.

## References

- Barberis A, Cherubini E, and Mozrzymas JW (2000) Zinc inhibits miniature GABAergic currents by allosteric modulation of GABAA receptor gating. *J Neurosci* **20**:8618–8627.
- Bhattacharya S and Linden J (1995) The allosteric enhancer, PD 81,723, stabilizes human  $A_1$  adenosine receptor coupling to G proteins. *Biochim Biophys Acta* **1265**: 15–21.
- Binder H, Arnold K, Ulrich AS, and Zschornig O (2001) Interaction of  $Zn^{2+}$  with phospholipid membranes. *Biophys Chem* **90**:57–74.
- Birnbaumer L and Birnbaumer M (1995) Signal transduction by G proteins: 1994 edition. *J Recept Signal Transduct Res* **15**:213–252.
- Chen N, Moshaver A, and Raymond LA (1997) Differential sensitivity of recombinant *N*-methyl-D-aspartate receptor subtypes to zinc inhibition. *Mol Pharmacol* **51**:1015–1023.
- Conigrave AD, Quinn SJ, and Brown EM (2000a) Cooperative multi-modal sensing and therapeutic implications of the extracellular  $Ca^{2+}$  sensing receptor. *Trends Pharmacol Sci* **21**:401–407.
- Conigrave AD, Quinn SJ, and Brown EM (2000b) L-Amino acid sensing by the extracellular  $Ca^{2+}$ -sensing receptor. *Proc Natl Acad Sci USA* **97**:4814–4819.
- Doi A, Kishimoto K, and Ishibashi H (1999) Modulation of glycine-induced currents by zinc and other metal cations in neurons acutely dissociated from the dorsal motor nucleus of the vagus of the rat. *Brain Res* **816**:424–430.
- Elling CE, Thirstrup K, Holst B, and Schwartz TW (1999) Conversion of agonist site to metal-ion chelator site in the  $\beta_2$ -adrenergic receptor. *Proc Natl Acad Sci USA* **96**:12322–12327.
- Horstman DA, Brandon S, Wilson AL, Guyer CA, Cragoe EJ, and Limbird LE (1990) An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium. *J Biol Chem* **265**:21590–21595.
- Huang EP (1997) Metal ions and synaptic transmission: think zinc. *Proc Natl Acad Sci USA* **94**:13386–13387.
- Hubbard PC and Lummis SC (2000)  $Zn^{2+}$  enhancement of the recombinant 5-HT(3) receptor is modulated by divalent cations. *Eur J Pharmacol* **394**:189–197.
- Jakubik J, Bacakova L, El-Fakahany EE, and Tucek S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. *Mol Pharmacol* **52**:172–179.
- Kobilka BK (1995) Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. *Anal Biochem* **231**: 269–271.
- Lee TW, Seifert R, Guan X, and Kobilka BK (1999) Restricting the mobility of Gs alpha: impact on receptor and effector coupling. *Biochemistry* **38**:13801–13809.
- Lim WK and Neubig RR (2001) Selective inactivation of guanine-nucleotide-binding regulatory protein (G-protein)  $\alpha$  and  $\beta\gamma$  subunits by urea. *Biochem J* **354**:337–344.
- Limbird LE (1984) GTP and  $Na^+$  modulate receptor-adenyl cyclase coupling and receptor-mediated function. *Am J Physiol* **247**:E59–E68.
- Lu ZL and Hulme EC (2000) A network of conserved intramolecular contacts defines the off-state of the transmembrane switch mechanism in a seven-transmembrane receptor. *J Biol Chem* **275**:5682–5686.
- Motulsky HJ and Insel PA (1983) Influence of sodium on the  $\alpha_2$ -adrenergic receptor system of human platelets. Role for intraplatelet sodium in receptor binding. *J Biol Chem* **258**:3913–3919.
- Musser B, Mudumbi RV, Liu J, Olson RD, and Vestal RE (1999) Adenosine  $A_1$  receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. *J Pharmacol Exp Ther* **288**:446–454.
- Neve KA (1991) Regulation of dopamine D2 receptors by sodium and pH. *Mol Pharmacol* **39**:570–578.
- Norregaard L, Frederiksen D, Nielsen EO, and Gether U (1998) Delineation of an endogenous zinc-binding site in the human dopamine transporter. *EMBO (Eur Mol Biol Organ) J* **17**:4266–4273.
- Schetz JA, Chu A, and Sibley DR (1999) Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. *J Pharmacol Exp Ther* **289**:956–964.
- Schetz JA and Sibley DR (1997) Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. *J Neurochem* **68**:1990–1997.
- Schetz JA and Sibley DR (2001) The binding-site crevice of the D(4) dopamine receptor is coupled to three distinct sites of allosteric modulation. *J Pharmacol Exp Ther* **296**:359–363.
- Sheikh SP, Vilardarga JP, Baranski TJ, Lichtarge O, Iiri T, Meng EC, Nissenson RA, and Bourne HR (1999) Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. *J Biol Chem* **274**:17033–17041.
- Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, and Bourne HR (1996) Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. *Nature (Lond)* **383**:347–350.
- Tesmer JJ, Sunahara RK, Johnson RA, Gosselin G, Gilman AG, and Sprang SR (1999) Two-metal-ion catalysis in adenylyl cyclase. *Science (Wash DC)* **285**:756–760.
- Thirstrup K, Elling CE, Hjorth SA, and Schwartz TW (1996) Construction of a high affinity zinc switch in the kappa-opioid receptor. *J Biol Chem* **271**:7875–7878.
- Tucek S and Proska J (1995) Allosteric modulation of muscarinic acetylcholine receptors. *Trends Pharmacol Sci* **16**:205–212.
- Weiss JH, Sensi SL, and Koh JY (2000)  $Zn^{2+}$  a novel ionic mediator of neural injury in brain disease. *Trends Pharmacol Sci* **21**:395–401.

---

**Address correspondence to:** Brian Kobilka, 157 Beckman Center, Stanford University, Stanford, CA 94305. E-mail: kobilka@stanford.edu

---